Medeloop is an AI-powered clinical research platform building an operating system for medical evidence - from grant discovery to real-world evidence generation to point-of-care intelligence. Founded by former surgeon Dr. Rene Caissie, the San Francisco company uses agentic AI to automate biostatistics, study monitoring, and protocol compliance for academic medical centers, health systems, and pharma.
ClinChoice is a mid-size, global, full-service contract research organization (CRO) that helps pharmaceutical, biotech, medical device, and consumer health companies run clinical trials and bring drugs and devices to market. Founded in 1995 and headquartered in Horsham, Pennsylvania, the firm employs roughly 4,000 people across the Americas, Europe, and Asia-Pacific, offering clinical development, biometrics, safety/pharmacovigilance, regulatory affairs, post-marketing real-world evidence, and technology services. After rebranding from Fountain Medical Development (FMD K&L) in 2020 and raising a $150M Series E in 2022, ClinChoice has grown through acquisitions to serve six of the top ten pharma companies while focusing on emerging and mid-size biotech innovators.
Curavit Clinical Research is a Boston-based, all-virtual Contract Research Organization (CRO) that designs and runs decentralized clinical trials. Through its Virtual Clinical Site and STRATUS platform, Curavit recruits, enrolls, and monitors diverse patient populations remotely - eliminating physical site infrastructure and travel while improving data quality. The company specializes in trials for digital therapeutics (DTx) and partners with sponsors and existing CROs to fix the execution layer of clinical research, accelerating timelines and lowering costs.
Carta Healthcare is a San Francisco health-tech company that pairs AI with expert nurse abstractors to pull clean, registry-ready data out of messy electronic medical records. Its Atlas and Lighthouse products cut abstraction costs by more than half while hitting 98-99% inter-rater reliability, freeing clinicians and hospitals from the slow, expensive grind of manual chart review.
Kardigan is a South San Francisco heart health company modernizing cardiovascular drug development. Founded by the team behind MyoKardia, it pairs a late-stage clinical pipeline in dilated cardiomyopathy, acute severe hypertension and calcific aortic valve stenosis with a 'cardiac intelligence' platform - real-world patient data and AI - to match disease drivers to the right responders.
Zack Scott is a General Partner and Co-Head of the Healthcare Investment Team at Norwest Venture Partners, one of Silicon Valley's most active multi-stage venture capital firms. A rare combination of clinically trained physician and seasoned investor, Scott brings an MD from UT Health San Antonio and an MBA from Duke's Fuqua School of Business to a career that spans surgical residency, healthcare venture investing at Burrill & Company, co-founding Revelation Partners (a healthcare-focused secondary investment firm), and now leading healthcare deals at Norwest. His portfolio includes companies like ShiraTronics, SetPoint Medical, Cytovale, and Galvanize Therapeutics, with notable exits including Omada Health's IPO and acquisitions by Stryker, Zoll Medical, Abbott, and Olympus.